New LabVantage Forensic Navigator™ Seamlessly Manages Vast Data Flows Over the Entire Forensic Life Cycle
25.4.2022 15:00:00 EEST | Business Wire | Press release
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced the introduction of LabVantage Forensic NavigatorTM, an industry expert-built informatics platform designed to seamlessly manage the vast amounts of forensic evidence and data used throughout the entire criminal justice life cycle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005012/en/
Forensic Navigator handles data flows in real time, from the evidence gathered at the crime scene through the ultimate resolution of the investigation. It accelerates the investigative process by streamlining, connecting, and analyzing all aspects of a criminal case, including evidence collection, property management, forensic lab analyses, medical examiner processes and reports, investigative activities, and legal proceedings. Forensic Navigator also includes critical tools to ensure quality management and regulatory compliance, in addition to forensic intelligence capabilities that allow users to gain insight from all data generated spanning investigations even across cases.
“LabVantage Forensic Navigator is a breakthrough informatics platform designed to increase the efficiency, effectiveness and accuracy of criminal justice operations,” said Mikael Hagstroem, Chief Executive Officer of LabVantage Solutions. “Forensic Navigator is built on the foundation of our industry-leading LIMS platform, but our developers went beyond those capabilities to produce a comprehensive system capable of managing and integrating the enormous amount of information generated during criminal investigations. At LabVantage we aim to bring the benefits of digital transformation to a variety of data-intensive industries, and we are proud to introduce this important new product purpose-built for the criminal justice sector, where data abounds and the stakes are so high.”
Forensic Navigator uses browser-based technology that is cloud hosted and is available in either SaaS or on-premise formats. It is a single, integrated, configurable platform that eliminates the need for customization. Forensic Navigator supports compliance with ISO17025, CALEA and other accreditations. It encompasses the entire forensic life cycle with best-in-class cybersecurity protection. Forensic Navigator’s forensics intelligence software provides insights from investigative data and is enhanced by predictive analysis through its forensic intelligence capabilities.
Robin MacDonald, PhD, Senior Product Specialist at LabVantage, spent more than a decade managing a forensic unit serving one of the largest counties in Florida. Dr. MacDonald noted, “The comprehensive data management capabilities of LabVantage Forensic Navigator would have been a huge help when I was a front-line forensic scientist at a busy law enforcement agency. In the complex, highly regulated criminal justice environment, Forensic Navigator’s ability to seamlessly manage all the evidence and data needed for investigations is a major advantage, eliminating the burden and inefficiency of implementing, maintaining, and coordinating multiple data management systems. It allows law enforcement personnel to enter data in real time, make examination requests and check status from a secure web-based portal. We offer a go-live plan that simplifies implementation and LabVantage’s track record of exceptional customer service means that expert user support is always available.”
Key advantages of LabVantage Forensic Navigator include:
- Advanced technology - HTML5-based platform with advanced predictive analytics via forensic intelligence.
- Browser-based - Cloud hosted and available in either SaaS or on-premise formats.
- Configurable - With industry best practices, including data integrity and cybersecurity protection.
- Online portal - For evidence pre-log, exam requests, status updates, and released reports.
- Dashboards - View all key performance indicators at a glance.
- Instruments - Integration and interface with most networkable instruments.
- Collaboration - Enables rapid access to shared data. Duplicative entry is never needed.
- Chain of custody - Includes person-to-person and person-to-secure-location transfers, with reporting options.
- Case management – Facilitates organizing all aspects of the case.
- Crime scene – Upload images and videos, capture scene-processing activities, and generate reports.
- Property management – Easily locate evidence and manage disposition activities.
- Medical examiner - Document external and autopsy observations, track next-of-kin, capture interviews.
- Laboratory – Track evidence through intake, examination assignment, testing, and reporting.
- Electronic lab notebook - Tracking support throughout the entire analytical life cycle.
- Reagents - Manage reagents, standards, and other laboratory consumables.
- Forensic intelligence - Pool siloed data for rapid resolution of cases and confidence in results.
- SDMS - Collect and secure files maintained throughout the lab with full traceability and search functions.
For more information on LabVantage Forensic Navigator click here or email info@labvantage.com.
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005012/en/
Contact information
Media:
Brandwidth Solutions LLC
Chris Anderson
Phone: 207-232-7007
Email: canderson@BWSmarketing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
